Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IntraDose with Paclitaxel and Carboplatin in Recurrent Head and Neck Cancer
NCT00022217Phase 2Unknown
- Sponsor
- Matrix Pharmaceutical
- Start
- Nov 2000
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cisplatin + epinephrine in head and neck squamous cell carcinoma (HNSCC), sponsored by Matrix Pharmaceutical. Primary endpoint: Antitumor Activity. Status: unknown.
02
Drugs
cisplatin + epinephrine
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT00022217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00022217.